辛伐他汀与熊去氧胆酸在肝硬化中的修复机制：胆汁分泌、肠道微生物组与宿主免疫应答的交互

数据集获取

源站：https://clinicaltrials.gov/study/NCT07102979

标准获取流程：

1. 访问源站链接，注册/登录账号；
2. 进入数据集详情页，按页面指引申请权限或直接下载；
3. 部分平台提供 SDK，例如：
   • OpenDataLab: pip install openxlab 后 openxlab.dataset.get(...)
   • ModelScope: pip install modelscope 后 modelscope download
   • 天池: 登录后页面提供直链下载
     以源站「数据下载/使用文档」页面为准。

数据说明

Conditions: Liver Fibrosis. BACKGROUND AND PURPOSE Patients with advanced liver fibrosis remain at risk of liver-related complications even after successful control of chronic hepatitis B or hepatitis C. Alterations in the gut microbiota and bile acid metabolism may contribute to persistent inflammation and fibrosis progression through the gut-liver axis. Ursodeoxycholic acid (UDCA) modifies the bile acid pool and may influence bile acid metabolism and signaling. Simvastatin may have anti-inflammatory, endothelial, and antifibrotic effects. This exploratory pilot study evaluated gut microbiota, fecal bile acid profiles, inflammatory markers, and fibrosis-related biomarkers in adults with chronic viral hepatitis after viral control. The study had two main objectives: first, to compare baseline biological characteristics between participants with and without advanced liver fibrosis; and second, to explore within-participant changes after six months of treatment with UDCA, simvastatin, or their combination. STUDY DESIGN This was a prospective, single-center, randomized, open-label exploratory pilot study. Participants with presumed advanced liver fibrosis were assigned by block randomization, with a planned 1:1:1:1 allocation, to one of four groups: Observation without study medication; UDCA 10 mg/kg/day for six months; Simvastatin 40 mg/day for six months; or Simvastatin 40 mg/day plus UDCA 10 mg/kg/day for six months. A separate non-randomized cohort of participants without advanced fibrosis was enrolled for baseline comparison. Eligible participants had chronic hepatitis B with viral suppression during antiviral therapy or chronic hepatitis C with sustained virologic response after antiviral treatment. During study enrollment, advanced liver fibrosis was operationally defined as a FibroScan liver stiffness measurement of at least 9.5 kPa. The non-advanced fibrosis comparison cohort was defined by a liver stiffness measurement of less than 6.0 kPa. ACTUAL ENROLLMENT AND FOLLOW-UP The study was

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。